Decisions of Incap Corporation's Annual General Meeting in

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 10, 2014 at 12:15 PM

Decisions of Incap Corporation's Annual General Meeting in 2014 and the Board of Directors

Incap Corporation Stock Exchange Release 10th April 2014 at 7 p.m. DECISIONS OF INCAP CORPORATION'S ANNUAL GENERAL MEETING IN 2014 AND THE BOARD OF DIRECTORS The Annual General Meeting of Incap Corporation was held on Thursday, 10 April 2014 in Helsinki. A total of 21 shareholders participated in the meeting, representing a total of 60,99 % of all shares and votes. Adoption of the annual accounts, resolution on the use of the profit shown on the balance sheet and the payment of dividend The Annual General Meeting adopted the annual accounts for the financial year ending at 31 December 2013. The Annual General Meeting decided in accordance with the proposal of the Board of Directors that no dividend will be distributed and that the loss for the financial year, a total of EUR 6,979,595.95, will be recognised in equity. The Annual General Meeting discharged the members of the Board of Directors and the President and CEO from liability. Changes to the Articles of the Association It was recorded that the paragraph of Articles of Association regarding the number of the Board members shall be changed as follows: "Article 5 Board of Directors: The Company shall have a Board of Directors with a minimum of three (3) and a maximum of seven (7) members. The Board of Directors elects amongst its number a Chairman. The term of office for the Board of Directors shall expire at the close of the next Annual General Meeting to take place after its election." The remuneration of the members of the Board of Directors and the auditor The Annual General Meeting decided that the fees for the members of the Board of Directors will be as follows: the annual fee to be paid for Chairman of the Board is EUR 25,000 and for the Board members EUR 17,500. Moreover, EUR 200 will be paid for each meeting for those who have been present. Eventual travel expenses are compensated according to the travel regulations of the company. The auditor is paid against an invoice. The resolution on the number of members of the Board of Directors Shareholders who represented over 40 % of the shares and votes changed their proposal regarding the number of members of the Board of Directors and proposed that the five (5) members would be elected to the Board of Directors. The amended proposal was supported by shareholders who represented circa 56 % of all shares and votes and circa 92 % of shares and votes present at the meeting. The Annual General Meeting decided that five (5) members will be elected to the Board of Directors. Members of the Board of Directors and the auditor The shareholders who represented over 40 % of the shares and votes changed their proposal regarding the members of the Board of Directors and proposed that in addition to earlier mentioned Lassi Noponen, Susanna Miekk-oja and Olle Hulteberg also Fredrik Berghel and Raimo Helasmäki would be elected as the members of the Board of Directors. The amended proposal was supported by shareholders who represented circa 56 % of all shares and votes and circa 92 % of shares and votes present at the meeting. Fredrik Berghel and Raimo Helasmäki gave their consent to the re-election at the meeting. Lassi Noponen, Susanna Miekk-oja and Olle Hulteberg had given their consent earlier. Raimo Helasmäki, Susanna Miekk-oja, Lassi Noponen, Olle Hulteberg and Fredrik Berghel were re-elected to the Board of Directors. Four members of the Board of Directors are independent of the company and three members are independent of its major shareholders. The firm of independent accountants Ernst & Young Oy was re-elected as the company's auditor, with Jari Karppinen, Authorised Public Accountant, as the principal auditor. In addition to above mentioned decisions the authorisation of the Board of Directors to decide on the issuance of shares as well as the issuance of other special rights entitling to shares was processed as follows: The shareholders who represented circa 56 % of all shares and votes and circa 92 % of shares and votes present at the meeting informed that they will oppose the proposal to authorise the Board of Directors to decide on the issuance of shares as well as the issuance of other special rights entitling to shares. Due to this opposing the Board of directors withdraw their proposal and the item was not discussed any further at the meeting. First meeting of the new Board of Directors The new Board of Directors held a meeting after the Annual General Meeting and elected Lassi Noponen as the Chairman of the Board. The minutes of the Annual General Meeting are available at the company's website as from 24 April 2014. INCAP CORPORATION Fredrik Berghel President and CEO Further information: Fredrik Berghel, President and CEO, tel. +46 73 202 2210 Kirsti Parvi, CFO, tel. +358 50 517 4569 DISTRIBUTION NASDAQ OMX Helsinki Ltd Principal media www.incap.fi Incap Corporation is an international contract manufacturer whose comprehensive services cover the entire life-cycle of electromechanical products from design and sourcing to actual manufacture and further to maintenance services. Incap's customers are leading suppliers of high-technology equipment in their own business segments, and Incap increases their competitiveness as a strategic partner. Incap has operations in Finland, Estonia, India and China. The Group's revenue in 2013 amounted to approximately EUR 36.8 million, and the company currently employs approximately 470 people. Incap's share has been listed on the NASDAQ OMX Helsinki Ltd since 1997. Additional information: www.incap.fi. [HUG#1776536]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...